ISRCTN86213744已完成不适用
A placebo controlled, flexible dose, randomised controlled trial to assess the efficacy of sildenafil citrate in men with erectile dysfunction after anterior resection for rectal carcinoma
niversity Hospital Birmingham NHS Foundation Trust (UK)0 个研究点目标入组 100 人开始时间: 2005年10月10日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Outpatients aged 18 years or over
- •2. Resection for tumours of the rectum, and where treatment has been completed
- •3. Diagnosis of erectile dysfunction (ED) confirmed by a Sexual Health Inventory-Male (SHI-M) score of 21 or less. Erectile dysfunction is defined as 'the inability to achieve and/or maintain an erection of the penis sufficient to permit satisfactory sexual performance' (Impotence National Institutes of Health [NIH] Consensus Conference, JAMA 1993, 270: 83-90).
- •4. In a stable relationship
- •5. Written informed consent obtained
排除标准
- •1. Unwilling or unable (i.e. not in a sexual relationship) to engage in sexual activity during the 12 week treatment period
- •2. Current prescription for and/or taking nitrates or nitric oxide donors in any form (oral, sublingual, transdermal, inhaled) on either a regular or intermittent basis
- •3. Current prescription for nicorandil
- •4. History of intolerance or hypersensitivity to morphine (or to any other opiates) or to any component of the tablet formulations of sildenafil
- •5. Previously prescribed pharmacological treatment for ED (any other non-pharmacological treatment (e.g. vacuum devices) for ED must be terminated on or before the screening visit and must not be used at any time during the study)
- •6. Receipt of a new, or a change to existing, medication known to be causally associated with ED such as but not limited to beta-blockers, thiazide diuretics or antidepressants, within the two weeks prior to screening
- •7. Concomitant treatment, due to requirement of dosage adjustment, with ritonavir, other protease inhibitors, erythromycin, ketoconazole, cimetidine or other CYP3A4 inhibitors
- •8. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol
- •9. Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study
- •10. Genital anatomical deformities that would significantly impair erections (e.g. severe penile fibrosis)
- •11. Predisposition to priapism
- •12. Active peptic ulcer
- •13. Requirement for a 25 mg starting dose of sildenafil, in the opinion of the investigator
- •14. Significant cardiovascular disease including cardiac failure, myocardial infarction, unstable angina, stroke, symptomatic or clinically significant cardiac arrhythmias in the last six months, uncontrolled hypertension, hypotension or history of postural hypotension, or judged by the investigator to be cardiovascularly unfit for sexual activity
- •15. Known history of retinitis pigmentosa
- •16. Any medical (including known history of major haematological, renal or hepatic abnormalities) or psychological condition or social circumstances that may increase risk to themselves or others by participating or would impair their ability to participate reliably in the study (unwilling or unable to complete Event Log worksheets or questionnaires consistently and accurately)
- •17. Intention to donate blood or blood products during the period of the study
研究者
相似试验
进行中（未招募）
1 期
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin(R) in acute ischemic hemispehric stroke - CERE-LYSE-1EUCTR2004-001729-11-SKEBEWE Pharma GesmbH Nfg.KG
进行中（未招募）
不适用
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke - CERE-LYSE-1Clinical diagnosis of ischemic stroke causing a measurable neurological deficitdefined as impairment of language, motor function, cognition and/or gaze,vision or neglect. Ischemic stroke is defined as an event characterised by thesudden onset of an acute focal neurologic deficit presumed to be due tocerebral ischemia after CT scan excludes haemorrhage. Onset of symptoms within 3 hours prior to initiation of rt-PA administrationMedDRA version: 6.0Level: LLTClassification code 10055221EUCTR2004-001729-11-SIEBEWE Pharma Ges.m.b.H Nfg.KG108
进行中（未招募）
1 期
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin(R) in acute ischemic hemispehric stroke - CERE-LYSE-1EUCTR2004-001729-11-CZEBEWE Pharma GesmbH Nfg.KG
进行中（未招募）
不适用
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke - CERE-LYSE-1EUCTR2004-001729-11-ATEBEWE Pharma Ges.m.b.H Nfg.KG108
进行中（未招募）
1 期
A prospective, randomized placebo controlled feasibility trial of faecal microbiota transplantation in cirrhosis.Cirrhosis of the liverMedDRA version: 20.0Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 100000004871EUCTR2017-003629-13-GBKing's College London32